These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 10991891

  • 1. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
    Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
    [Abstract] [Full Text] [Related]

  • 2. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
    Ji B, Grosset J.
    Lepr Rev; 2000 Dec; 71 Suppl():S81-7. PubMed ID: 11201894
    [Abstract] [Full Text] [Related]

  • 3. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
    Ji B, Perani EG, Petinon C, Grosset JH.
    Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):556-61. PubMed ID: 1338596
    [Abstract] [Full Text] [Related]

  • 4. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
    Ji B, Perani EG, Petinom C, Grosset JH.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):393-9. PubMed ID: 8834886
    [Abstract] [Full Text] [Related]

  • 5. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.
    Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J.
    Antimicrob Agents Chemother; 1998 May; 42(5):1115-20. PubMed ID: 9593137
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.
    Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, Grosset JH.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2137-41. PubMed ID: 8878595
    [Abstract] [Full Text] [Related]

  • 8. Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
    Lenz SM, Collins JH, Ray NA, Hagge DA, Lahiri R, Adams LB.
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008583. PubMed ID: 32936818
    [Abstract] [Full Text] [Related]

  • 9. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.
    Burgos J, de la Cruz E, Paredes R, Andaya CR, Gelber RH.
    Lepr Rev; 2011 Sep; 82(3):253-8. PubMed ID: 22125933
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P, Ponnaiya J, Das M, Chaitanya VS, Arumugam S, Ebenezer M.
    Indian J Lepr; 2016 Sep; 88(3):147-58. PubMed ID: 30207440
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
    Ji B, Chauffour A, Andries K, Jarlier V.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1558-60. PubMed ID: 16569884
    [Abstract] [Full Text] [Related]

  • 12. Newer drugs in leprosy.
    Grosset JH.
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [Abstract] [Full Text] [Related]

  • 13. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
    Ji BH, Chen JK, Lu XZ, Wang SY, Ni GX, Hou YH, Zhou DH, Tang QK.
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
    [Abstract] [Full Text] [Related]

  • 14. Powerful bactericidal activity of moxifloxacin in human leprosy.
    Pardillo FE, Burgos J, Fajardo TT, Dela Cruz E, Abalos RM, Paredes RM, Andaya CE, Gelber RH.
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3113-7. PubMed ID: 18573938
    [Abstract] [Full Text] [Related]

  • 15. [In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
    Gidoh M.
    Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):11-7. PubMed ID: 17315747
    [Abstract] [Full Text] [Related]

  • 16. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M, Kashiwabara Y, Namisato M.
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [Abstract] [Full Text] [Related]

  • 17. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.
    Banerjee DK, McDermott-Lancaster RD, McKenzie S.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):326-30. PubMed ID: 9021187
    [Abstract] [Full Text] [Related]

  • 18. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
    Dhople AM, Namba K.
    Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
    [Abstract] [Full Text] [Related]

  • 19. Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
    Schülin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulos GM.
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1520-3. PubMed ID: 9624509
    [Abstract] [Full Text] [Related]

  • 20. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice.
    Xiong JH, Ji B, Perani EG, Pétinon C, Grosset JH.
    Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):37-42. PubMed ID: 8189087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.